Loss of intercellular adhesion activates a transition from low- to high-grade human squamous cell carcinoma

International Journal of Cancer

Volumn 118, Issue 4, 2006, Pages 821-831

  Margulis, Alexander ^a   Zhang, Weitian ^a   Alt Holland, Addy ^a   Pawagi, Sujata ^b   Prabhu, Padmaja ^b   Cao, Jian ^c   Zucker, Stanley ^c,d   Pfeiffer, Laurence ^b   Garfield, Jacqueline ^e   Fusenig, Norbert E ^f   Garlick, Jonathan A ^a,g  

^a TUFTS UNIVERSITY SCHOOL OF DENTAL MEDICINE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e LIFECELL CORPORATION   (United States)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g TUFTS UNIVERSITY   (United States)

Author keywords

E cadherin; Laminin 5; Matrix metalloproteinase; Squamous cell carcinoma; Tumor microenvironment

Indexed keywords

COLLAGEN TYPE 4; CYTOKERATIN 1; ILOMASTAT; KALININ; LAMININ 5 GAMMA2; MATRIX METALLOPROTEINASE; NERVE CELL ADHESION MOLECULE; PROTEINASE; SCLEROPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INFILTRATION; CANCER TRANSPLANTATION; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GEL; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STROMA; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; KERATIN-1; KERATINS; LAMININ; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROGNOSIS; SKIN NEOPLASMS; TISSUE CULTURE TECHNIQUES;

EID: 31544441678     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21409     Document Type: Article

References (59)

1. Andrews NA, Jones AS, Helliwell TR, Kinsella AR. Expression of the E-cadherin-catenin cell adhesion complex in primary squamous cell carcinomas of the head and neck and their nodal metastases. Br J Cancer 1997;75:1474-80.
2. Behrens J. Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev 1999;18:15-30.
3. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994;1198:11-26.
4. Bagutti C, Speight PM, Watt FM. Comparison of integrin, cadherin, and catenin expression in squamous cell carcinomas of the oral cavity. JPathol 1998;186:8-16.
5. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998;392:190-3.
6. Yap AS. The morphogenetic role of cadherin cell adhesion molecules in human cancer: a thematic review. Cancer Invest 1998;16:252-61.
7. Behrens J, Mareel MM, Van Roy FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989;108:2435-47.
8. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991;113:173-85.
9. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, Van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991;66:107-19.
10. Noe V, Willems J, Vandekerckhove J, Roy FV, Bruyneel E, Mareel M. Inhibition of adhesion and induction of epithelial cell invasion by HAV-containing E-cadherin-specific peptides. J Cell Sci 1999;112(Pt 1):127-35.
11. Cano A, Gamallo C, Kemp CJ, Benito N, Palacios J, Quintanilla M, Balmain A. Expression pattern of the cell adhesion molecules. E-cadherin, P-cadherin and alpha 6 beta 4 intergrin is altered in pre-malignant skin tumors of p53-deficient mice. Int J Cancer 1996;65:254-62.
12. de Boer CJ, van Dorst E, van Krieken H, Jansen-van Rhijn CM, Warnaar SO, Fleuren GJ, Litvinov SV. Changing roles of cadherins and catenins during progression of squamous intraepithelial lesions in the uterine cervix. Am J Pathol 1999;155:505-15.
13. Bindels EM, Vermey M, van den Beemd R, Dinjens WN, Van Der Kwast TH. E-cadherin promotes intraepithelial expansion of bladder carcinoma cells in an in vitro model of carcinoma in situ. Cancer Res 2000;60:177-83.
14. Auersperg N, Pan J, Grove BD, Peterson T, Fisher J, Maines-Bandiera S, Somasiri A, Roskelley CD. E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci USA 1999;96:6249-54.
15. Hagios C, Lochter A, Bissell MJ. Tissue architecture: the ultimate regulator of epithelial function? Philos Trans R Soc Lond B Biol Sci 1998;353:857-70.
16. Javaherian A, Vaccariello M, Fusenig NE, Garlick JA. Normal keratinocytes suppress early stages of neoplastic progression in stratified epithelium. Cancer Res 1998;58:2200-8.
17. Javaherian A, Fusenig NE, Vaccariello M, Garlick JA. A tissue model for premalignancy in stratified epithelium: bioengineering of skin substitutes. 1998. 183-208.
18. Andriani F, Margulis A, Lin N, Griffey S, Garlick JA. Analysis of microenvironmental factors contributing to basement membrane assembly and normalized epidermal phenotype. J Invest Dermatol 2003;120:923-31.
19. Boukamp P, Breitkreutz D, Stark H-J, Fusenig NE. Mesenchyme-mediated and endogenous regulation of growth and differentiation of human skin keratinocytes derived from diffferent body sites. Differentiation 1990;44:150-61.
20. Boukamp P, Stanbridge EJ, Foo DY, Cerutti PA, Fusenig NE. c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res 1990;50:2840-7.
21. Fusenig NE, Boukamp P. Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinogen 1998;23: 144-58.
22. Zhu AJ, Watt FM. Expression of a dominant negative cadherin mutant inhibits proliferation and stimulates terminal differentiation of human epidermal keratinocytes. J Cell Sci 1996;109:3013-23.
23. Margulis A, Andriani F, Fusenig N, Hashimoto K, Hanakawa Y, Garlick JA. Abrogation of E-cadherin-mediated adhesion induces tumor cell invasion in human skin-like organotypic cultures. J Invest Dermatol 2003;121:1182-90.
24. Vasioukhin V, Bauer C, Yin M, Fuchs E. Directed actin polymerization is the driving force for epithelial cell-cell adhesion. Cell 2000; 100:209-19.
25. Margulis A, Zhang W, Alt-Holland A, Crawford H, Fusenig N, Garlick J. E-cadherin suppression accelerates squamous cell carcinoma progression in 3D, human tissue constructs. Cancer Res 2005;65: 1783-91.
26. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54.
27. Papadavid E, Pignatelli M, Zakynthinos S, Krausz T, Chu AC. Abnormal immunoreactivity of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex in premalignant and malignant non-melanocytic skin tumours. J Pathol 2002;196:154-62.
28. Sun W, Herrera GA. E-cadherin expression in invasive urothelial carcinoma. Ann Diagn Pathol 2004;8:17-22.
29. Behrendt GC, Hansmann ML. Carcinomas of the anal canal and anal margin differ in their expression of cadherin, cytokeratins and p53. Virch Arch 2001;439:782-6.
30. Wu H, Lotan R, Menter D, Lippman SM, Xu XC. Expression of E-cadherin is associated with squamous differentiation in squamous cell carcinomas. Anticancer Res 2000;20:1385-90.
31. Rheinwald JG, Beckett MA. Defective terminal differentiation in culture as a consistent and selectable character of malignant human keratinocytes. Cell 1980;22:629-32.
32. Wheelock MJ, Jensen PJ. Regulation of keratinocyte intercellular junction organization and epidermal morphogenesis by E-cadherin. J Cell Biol 1992;117:415-25.
33. Stoltzfus P, Salo S, Eriksson E, Aspenblad U, Tryggvason K, Auer G, Avall-Lundqvist E. Laminin-5 gamma2 chain expression facilitates detection of invasive squamous cell carcinoma of the uterine cervix. Int J Gynecol Pathol 2004;23:215-22.
34. Ono Y, Nakanishi Y, Gotoh M, Sakamoto M, Hirohashi S. Epidermal growth factor receptor gene amplification is correlated with laminin-5 gamma2 chain expression in oral squamous cell carcinoma cell lines. Cancer Lett 2002;175:197-204.
35. Pyke C, Romer J, Kallunki P, Lund LR, Ralfkiaer E, Dano K, Tryggvason K. The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol 1994;145:782-91.
36. Shinohara M, Nakamura S, Harada T, Shimada M, Oka M. Mode of tumor invasion in oral squamous cell carcinoma: improved grading based on immunohistochemical examination of extracellular matrices. Head Neck 1996;18:153-9,
37. Pyke C, Salo S, Ralfkiaer E, Romer J, Dano K, Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res 1995;55:4132-9.
38. Patel V, Aldridge K, Ensley JF, Odell E, Boyd A, Jones J, Gutkind JS, Yeudall WA. Laminin-gamma2 overexpression in head-and-neck squamous cell carcinoma. Int J Cancer 2002;99:583-8.
39. Sordat I, Rousselle P, Chaubert P, Petermann O, Aberdam D, Bosman FT, Sordat B. Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environment. Int J Cancer 2000;88:708-17.
40. Sordat I, Bosman FT, Dorta G, Rousselle P, Aberdam D, Blum AL, Sordat B. Differential expression of laminin-5 subunits and integrin receptors in human colorectal neoplasia. J Pathol 1998;185:44-52.
41. Lohi J. Laminin-5 in the progression of carcinomas. Int J Cancer 2001;94:763-7.
42. Baumann P, Zigrino P, Mauch C, Breitkreutz D, Nischt R. Membrane-type 1 matrix metalloproteinase-mediated progelatinase A activation in non-tumorigenic and tumorigenic human keratinocytes. Br J Cancer 2000;83:1387-93.
43. Koike T, Vernon RB, Hamner MA, Sadoun E, Reed MJ. MT1-MMP, but not secreted MMPs, influences the migration of human microvascular endothelial cells in 3-dimensional collagen gels. J Cell Biochem 2002;86:748-58.
44. Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000;148:615-24.
45. Takino T, Miyamori H, Watanabe Y, Yoshioka K, Seiki M, Sato H. Membrane type 1 matrix metalloproteinase regulates collagen-dependent mitogen-activated protein/extracellular signal-related kinase activation and cell migration. Cancer Res 2004;64:1044-9.
46. Horary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003;114:33-45.
47. D'Ortho MP, Stanton H, Butler M, Atkinson SJ, Murphy G, Hembry RM. MT1-MMP on the cell surface causes focal degradation of gelatin films. FEBS Lett 1998;421:159-64.
48. Atkinson SJ, Crabbe T, Cowell S, Ward RV, Butler MJ, Sato H, Seiki M, Reynolds JJ, Murphy G. Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J Biol Chem 1995;270:30479-85.
49. Will H, Atkinson SJ, Butler GS, Smith B, Murphy G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation: regulation by TIMP-2 and TIMP-3. J Biol Chem 1996;271:17119-23.
50. Lichte A, Kolkenbrock H, Tschesche H. The recombinant catalytic domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) induces activation of progelatinase A and progelatinase A complexed with TIMP-2. FEBS Lett 1996;397:277-82.
51. Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, van Westrum SS, Crabbe T, Clements J, D'Ortho MP, Murphy G. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A: a kinetic study. J Biol Chem 1998;273:871-80.
52. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
53. Boukamp P, Fusenig NE. "Trans-differentiation" from epidermal to mesenchymal/myogenic phenotype is associated with a drastic change in cell-cell and cell-matrix adhesion molecules. J Cell Biol 1993; 120:981-93.
54. Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression, Ann NY Acad Sci 2004;1014:155-63.
55. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 2001;61:3819-25.
56. Granville DJ, Carthy CM, Hunt DW, McManus BM. Apoptosis: molecular aspects of cell death and disease. Lab Invest 1998;78:893-913.
57. Shelly LL, Fuchs C, Miele L. Notch-1 inhibits apoptosis in murine erythroleukemia cells and is necessary for differentiation induced by hybrid polar compounds. J Cell Biochem 1999;73:164-75.
58. Takahashi M, Fujita M, Furukawa Y, Hamamoto R, Shimokawa T, Miwa N, Ogawa M, Nakamura Y. Isolation of a novel human gene. APCDD1, as a direct target of the beta-catenin/T-cell factor 4 complex with probable involvement in colorectal carcinogenesis. Cancer Res 2002;62.
59. Dlugosz A, Merlino G, Yuspa SH. Progress in cutaneous cancer research. J Invest Dermatol Symp Proc 2002;7:17-26.